

Daniela Bianconi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6272699/publications.pdf>

Version: 2024-02-01

22
papers

290
citations

1040056

9
h-index

888059

17
g-index

22
all docs

22
docs citations

22
times ranked

759
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior. <i>Journal of Cancer</i> , 2022, 13, 2271-2280.	2.5	2
2	Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing. <i>Cancer Management and Research</i> , 2021, Volume 13, 6249-6261.	1.9	2
3	Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092863.	3.2	12
4	Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 1772.	2.4	3
5	Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 648.	2.4	24
6	A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	3.2	29
7	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. <i>ESMO Open</i> , 2019, 4, e000538.	4.5	7
8	Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy. <i>Medical Oncology</i> , 2019, 36, 1.	2.5	14
9	SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment. <i>Translational Oncology</i> , 2019, 12, 15-23.	3.7	8
10	Impact of new chemotherapy regimens on the treatment landscape and survival of advanced pancreatic cancer (PAC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 403-403.	1.6	1
11	Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <i>Oncotarget</i> , 2019, 10, 942-952.	1.8	11
12	Efficacy of liposomal-irinotecan (nal-IRI) plus 5-fluorouracil/folinic acid (5-FU/LV) versus oxaliplatin plus fluoropyrimidines in previous gemcitabine treated pancreatic adenocarcinoma (PAC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 383-383.	1.6	0
13	Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI. <i>Oncology</i> , 2018, 94, 306-310.	1.9	5
14	Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018, 17, 274-279.	2.3	17
15	Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 508-515.	2.2	2
16	Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 136-140.	0.5	5
17	Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel. <i>Scientific Reports</i> , 2017, 7, 4851.	3.3	5
18	Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 604-604.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 588-594.	1.4	6
20	Integrins in the Spotlight of Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2037.	4.1	111
21	Effects of cilengitide in osteoclast maturation and behavior. <i>Experimental Cell Research</i> , 2015, 337, 68-75.	2.6	9
22	Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. <i>Thrombosis Research</i> , 2015, 136, 865-869.	1.7	16